Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Upcoming efficacy % @360-days
View:
Post by ScienceFirst on Aug 09, 2022 9:44am

Upcoming efficacy % @360-days

Lets now focus on the 360-days milestone.  For the TR (CR + PR), we currently stand at 39%.
 
Now, 
 
... if 4 patients out of these 18 pending turn CR @360-days, then 13 (5 + 4 + 4) out of 41 patients = 32% @360-days 
... if 5 patients out of these 18 pending turn CR @360-days, then 14 (5 + 4 + 5) out of 41 patients = 34% @360-days
... if 6 patients out of these 18 pending turn CR @360-days, then 15 (5 + 4 + 6) out of 41 patients = 37% @360-days
... if 7 patients out of these 18 pending turn CR @360-days, then 16 (5 + 4 + 7) out of 41 patients = 39% @360-days
... if 8 patients out of these 18 pending turn CR @360-days, then 17 (5 + 4 + 8) out of 41 patients = 41% @360-days
... if 9 patients out of these 18 pending turn CR @360-days, then 18 (5 + 4 + 9) out of 41 patients = 44% @360-days

If more than 9 patients out of these 18 pending turn CR, then that's amazing as some of them might be from the 12 underdosed cohort.  That's why I play it safe by stopping at 9.
Comment by 99942Apophis on Aug 09, 2022 10:26am
ScienceFirst wrote  Lets now focus on the 360-days milestone.  For the TR (CR + PR), we currently stand at 39%.   Now,    ... if 4 patients out of these 18 pending turn CR @360-days, then 13 (5 + 4 + 4) out of 41 patients = 32% @360-days  ... if 5 patients out of these 18 pending turn CR @360-days, then 14 (5 + 4 + 5) out of 41 patients = 34% @360-days  ...more  
Comment by ScienceFirst on Aug 09, 2022 7:11pm
After analysis, and given that our p#12 has reached its 450-day period by Nov. 23, 2021, we have the right to be more optimistic about our %CR scenarios.  So I added 9 more possiblities to my previous post.   ... if 9 patients out of these 18 pending turn CR @360-days, then 18 (5 + 4 + 9) out of 41 patients = 44% @360-days ... if 10 patients out of these 18 pending turn CR ...more  
Comment by Rumpl3StiltSkin on Aug 10, 2022 9:54am
I agree SF. I think your numbers look correct here and probably conservative. I also think they won't get worse at the 450 day mark. :-)
Comment by Legit62 on Aug 10, 2022 1:06pm
SF. What % do u think will get us BTD? I know in last updated news they were very optimistic about getting BTD and AA at or near end of year
Comment by ScienceFirst on Aug 10, 2022 1:43pm
I think the low number of treatments, mixed with high potency, low toxicity, the fact we don't rely on BCG and that we're a standalone treatment will be the factors the FDA value. If we approch ImmuneBio efficacy numbers, then that's a done deal.
Comment by Rumpl3StiltSkin on Aug 10, 2022 2:59pm
Low tox means repeatability. Try, try again!
Comment by ScienceFirst on Aug 10, 2022 4:42pm
If BCG has been able to be given 10-24x to patients, there's no reason for us to give it 3-4x for cases that might not deliver CR @450-days. We have a possibility to displace BCG totally.  We just need more data to confirm it.  And our TLD1433 is also good for MIBC, which is not the case for BCG.  Chemo is required.  So between TLD1433 and chemo for MIBC, the choice will ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250